论文部分内容阅读
基因病毒工程国家重点实验室的常务主任金奇,除了做与传染病有关的项目研究之外,正在积极与华北制药集团和大庆油田合作,解决用微生物生产Vc和提高石油产量的难题。金奇在“863”计划里承担了两个课题,其中一个就是破译用于生产Vc菌株的基因组。Vc是我国重大战略医药品种之一,中科院早在十几年前,就发明了一种Vc发酵生产法,这种方法没有污染,而且产量高,但是需要特定的生产菌株,因此,国家把生产菌株的功能基因研究列进“863”计划。现在,金奇带领的课题组,与华北制药集团合作,利用基因组、芯片和分子生物学等技术,已经把菌株的基因测序完毕。
In addition to doing research on infectious diseases, Jin Qi, executive director of the State Key Laboratory of Genetics and Virology, is actively cooperating with North China Pharmaceutical Group and Daqing Oilfield to solve the problem of producing Vc with microorganisms and raising oil output. One of the two topics that Jinqi undertook in the “863” program was to decipher the genome used to produce the Vc strain. Vc is one of China's major strategic pharmaceutical varieties. As early as more than 10 years ago, Chinese Academy of Sciences invented a Vc fermentation production method. This method has no pollution and high yield, but requires specific production strains. Therefore, Strains of functional genes included in the “863” program. Now, Jinqi led group, in cooperation with North China Pharmaceutical Group, the use of genomics, microarrays and molecular biology techniques, the strains have been gene sequencing completed.